Floatz logo

Pd-L1 T-Hank

Small Cell Lung Cancer

ImmunityBio, Inc.Cell therapyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

290 Active assets in the Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Pd-L1 T-Hank is also rated in:

Microsatellite InstabilityDormant
CCC
Indicative ·
53 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair DeficiencyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →